Compare SDA & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | MDWD |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.2M | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | SDA | MDWD |
|---|---|---|
| Price | $2.05 | $17.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.75 | ★ $37.50 |
| AVG Volume (30 Days) | 47.2K | ★ 91.0K |
| Earning Date | 12-18-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,272,000.00 | $20,932,000.00 |
| Revenue This Year | $10.86 | $15.89 |
| Revenue Next Year | $13.07 | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.69 | 6.15 |
| 52 Week Low | $1.54 | $14.14 |
| 52 Week High | $10.61 | $22.51 |
| Indicator | SDA | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 38.61 |
| Support Level | $2.02 | $16.32 |
| Resistance Level | $2.15 | $19.70 |
| Average True Range (ATR) | 0.09 | 0.74 |
| MACD | 0.00 | -0.23 |
| Stochastic Oscillator | 57.14 | 23.37 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.